Kaken Pharmaceutical Co (TSE:4521) COGS-to-Revenue : 0.45 (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co COGS-to-Revenue?

Kaken Pharmaceutical Co's Cost of Goods Sold for the three months ended in Dec. 2023 was 円8,374 Mil. Its Revenue for the three months ended in Dec. 2023 was 円18,514 Mil.

Kaken Pharmaceutical Co's COGS to Revenue for the three months ended in Dec. 2023 was 0.45.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kaken Pharmaceutical Co's Gross Margin % for the three months ended in Dec. 2023 was 54.77%.

Kaken Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Kaken Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co COGS-to-Revenue Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.43

0.45

0.46

0.47

Kaken Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.48	0.45	0.46	0.45	0.50

Kaken Pharmaceutical Co COGS-to-Revenue Calculation

Kaken Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	33505	/	72044
	=	0.47

Kaken Pharmaceutical Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8374	/	18514
	=	0.45

Kaken Pharmaceutical Co (TSE:4521) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kaken Pharmaceutical Co's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	8374 / 18514
	=	54.77 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Kaken Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines